title: Piceatannol suppresses endotoxin-induced ocular inflammation in rats.
abstract: Anti-inflammatory effect of piceatannol, a naturally occurring polyphenol and a potent free radical scavenger, on ocular inflammation is not known. We examined the anti-inflammatory role of piceatannol in ocular inflammatory response due to endotoxin-induced uveitis (EIU) in rats. EIU was induced in Lewis rats by subcutaneous injection of lipopolysaccharide (LPS; 150 ug/rat). Piceatannol (30mg/kg body wt, i.p) was injected either 2h prior to or 1h post LPS induction. A significant increase in the number of infiltrating cells, total protein, and various cytokines and chemokines in AqH were observed in the EIU rat eyes as compared to control groups. However, pre- or post-treatment of piceatannol significantly blocked the LPS-induced changes. Further, piceatannol also suppressed the expression of cyclooxygenase-2 (Cox-2), inducible nitric oxide synthase (iNOS) and activation of NF-κB in the ciliary bodies as well as retina. Further, piceatannol also inhibited the expression of Cox-2, iNOS, and phosphorylation of NF-κB in primary human non-pigmented ciliary epithelial cells (HNPECs) treated with LPS. Similarly, piceatannol also diminished LPS-induced level of NO and prostaglandin E2 in HNPECs. Thus our results demonstrate an anti-inflammatory role of piceatannol in suppressing ocular inflammation induced by endotoxin in rats.
authors.affiliation: Department of Ophthalmology & Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA.
authors.forename: Nilesh M
authors.initials: NM
authors.lastname: Kalariya
authors.forename: Mohammad
authors.initials: M
authors.lastname: Shoeb
authors.forename: Aramati B M
authors.initials: AB
authors.lastname: Reddy
authors.forename: Rahul
authors.initials: R
authors.lastname: Sawhney
authors.forename: Kota V
authors.initials: KV
authors.lastname: Ramana
mesh_terms: D000818:Animals; D001082:Aqueous Humor / Q000187:drug effects* / Q000276:immunology; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D016166:Free Radical Scavengers / Q000008:administration & dosage*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology; D006801:Humans; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D012160:Retina / Q000187:drug effects / Q000276:immunology*; D012772:Shock, Septic / Q000188:drug therapy* / Q000276:immunology; D013267:Stilbenes / Q000008:administration & dosage*; D014605:Uveitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology
chemical_list: D016207:Cytokines; D016166:Free Radical Scavengers; D016328:NF-kappa B; D013267:Stilbenes; C041525:3,3',4,5'-tetrahydroxystilbene; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; C489691:Ptgs2 protein, rat
keywords: Inflammation; NF-κB; Piceatannol; Rats; Uveitis
references.citation: Nutr Cancer. 2009;61(6):855-63
references.pmid: 20155627
references.citation: Ocul Immunol Inflamm. 2008 Sep-Oct;16(5):211-6
references.pmid: 19065415
references.citation: Chem Phys Lipids. 2008 Sep;155(1):48-56
references.pmid: 18590713
references.citation: Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5105-13
references.pmid: 20435582
references.citation: J Appl Toxicol. 2012 Dec;32(12):986-93
references.pmid: 21935971
references.citation: Cardiovasc Res. 2010 Mar 1;85(4):836-44
references.pmid: 19887493
references.citation: Ophthalmology. 2011 Jan;118(1):184-90
references.pmid: 20678806
references.citation: Carcinogenesis. 2010 Aug;31(8):1442-9
references.pmid: 20584749
references.citation: Invest Ophthalmol Vis Sci. 2011 Aug 22;52(9):6565-71
references.pmid: 21775660
references.citation: J Immunol. 2002 Dec 1;169(11):6490-7
references.pmid: 12444159
references.citation: Curr Opin Ophthalmol. 2000 Dec;11(6):478-83
references.pmid: 11141645
references.citation: Nutr Cancer. 2009;61(6):847-54
references.pmid: 20155626
references.citation: Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3873-83
references.pmid: 7928184
references.citation: Int Immunopharmacol. 2008 Dec 10;8(12):1695-702
references.pmid: 18773974
references.citation: Antioxid Redox Signal. 2013 Apr 10;18(11):1249-62
references.pmid: 22978663
references.citation: Mol Vis. 2011 Jan 18;17:170-6
references.pmid: 21264236
references.citation: Curr Opin Ophthalmol. 2006 Dec;17(6):532-7
references.pmid: 17065921
references.citation: Food Chem Toxicol. 2007 Oct;45(10):1899-909
references.pmid: 17560706
references.citation: Nippon Ganka Gakkai Zasshi. 2010 Nov;114(11):944-54
references.pmid: 21141074
references.citation: Mol Nutr Food Res. 2005 May;49(5):431-42
references.pmid: 15779068
references.citation: FEBS Lett. 2011 Nov 4;585(21):3457-64
references.pmid: 22001200
references.citation: Immunol Lett. 2008 Oct 30;120(1-2):1-5
references.pmid: 18694783
references.citation: Eur J Nutr. 2004 Oct;43(5):275-84
references.pmid: 15309446
references.citation: Biochim Biophys Acta. 2009 Sep;1788(9):1851-60
references.pmid: 19527681
references.citation: Pharmacol Res. 2006 Feb;53(2):113-22
references.pmid: 16243536
references.citation: Invest Ophthalmol Vis Sci. 2011 Jul 11;52(8):5144-52
references.pmid: 21551413
references.citation: Mutat Res. 2012 Jan-Mar;750(1):60-82
references.pmid: 22108298
references.citation: Curr Protoc Immunol. 2003 May;Chapter 15:15.6.1-15.6.20
references.pmid: 18432901
references.citation: Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4634-42
references.pmid: 17898287
references.citation: Invest Ophthalmol Vis Sci. 2011 Oct 17;52(11):8076-85
references.pmid: 21911582
references.citation: Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2562-8
references.pmid: 16723471
references.citation: Pharmacol Res. 2006 Dec;54(6):461-7
references.pmid: 17067811
references.citation: Exp Eye Res. 2006 Feb;82(2):275-81
references.pmid: 16126197
references.citation: Oncol Rep. 2006 Sep;16(3):617-24
references.pmid: 16865264
references.citation: Int Ophthalmol. 1990 Oct;14(5-6):303-8
references.pmid: 2249907
references.citation: Anticancer Res. 2004 Sep-Oct;24(5A):2783-840
references.pmid: 15517885